Pregabalin Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, Canada, China, Japan - Size and Forecast 2024-2028

Pregabalin Market Size 2024-2028

The pregabalin market size is forecast to increase by USD 133 million at a CAGR of 3.27% between 2023 and 2028.

• The herbal supplement market for mental health, including pregabalin, is experiencing significant growth due to several key factors. The presence of a substantial patient population suffering from neuropathic pain is driving market expansion. Additionally, there is a rising focus on emerging economies as potential growth markets, as mental health awareness and access to healthcare improve In these regions.
• Furthermore, there is a growing preference for herbal alternatives to traditional pharmaceuticals, as consumers seek more natural solutions for managing their conditions. These trends are expected to continue shaping the herbal supplement market for pregabalin and other mental health treatments In the coming years.

What will be the Size of the Pregabalin Market During the Forecast Period?

Request Free Sample

• The market encompasses the production, distribution, and consumption of pregabalin, an anticonvulsant medication used primarily for managing various neurological conditions. Neuropathic pain, including diabetic peripheral neuropathy and postherpetic neuralgia, is a significant application area for pregabalin. Additionally, it is indicated for the treatment of anxiety and seizures, particularly in epilepsy and generalized anxiety disorder.
• The World Health Organization estimates that approximately 10% of the global population experiences chronic pain, making it a substantial market for pregabalin. The geriatric population, with a higher prevalence of neurological disorders, also represents a significant consumer base. Pregabalin is available in various oral dosage forms, including capsules, tablets, and solutions, which are readily accessible through drug stores and retail pharmacies.
• As a calcium channel alpha-2 delta ligand, pregabalin modulates neurotransmitter release In the central nervous system, offering relief for those suffering from neuropathic pain, anxiety, and seizures.

How is this Pregabalin Industry segmented and which is the largest segment?

The pregabalin industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Application
  • Neuropathic pain
  • Epilepsy
  • Anxiety disorders
  • Others
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
  • Asia
    • China
    • Japan
  • Rest of World (ROW)

By Application Insights

• The neuropathic pain segment is estimated to witness significant growth during the forecast period.

Neuropathic pain is a debilitating condition characterized by damage or dysfunction of nerve fibers, resulting in incorrect pain signals to the brain. Causes include diabetes, chemotherapy, alcoholism, and various neurological disorders. The World Health Organization estimates that over 7% of the global population experiences neuropathic pain. This condition is prevalent In the geriatric population due to age-related degeneration and the increasing number of individuals with diabetes. Pharmaceutical companies, are investing in new treatments, including Pregabalin, an anticonvulsant medication used to treat various conditions, including neuropathic pain, anxiety disorders, fibromyalgia, and epilepsy. Pregabalin is available in various oral dosage forms, including capsules, oral solutions, and oral tablets.

Healthcare facilities, including hospitals, specialty clinics, homecare, hospital pharmacy, retail pharmacy, and online pharmacy, provide access to these medications. Anxiety disorders, such as generalized anxiety disorder and post-traumatic stress disorder, are also treated with anxiolytic medications like Pregabalin. Other conditions treated with anticonvulsants include restless leg syndrome and seizures. Patient preference and accessibility influence the choice of healthcare products and services.

Get a glance at the Pregabalin Industry report of share of various segments Request Free Sample

The Neuropathic pain segment was valued at USD 254.40 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• Europe is estimated to contribute 30% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The North American market is projected to lead The market due to the high prevalence of diabetes, epilepsy, and anxiety disorders. According to the CDC, approximately 30.3 million Americans have diabetes, increasing the risk of diabetic neuropathy, a nerve disorder causing pain. Additionally, the aging population and the increasing adoption of pregabalin for new indications, such as fibromyalgia and postherpetic neuralgia, will boost market growth. Pregabalin is an anticonvulsant medication used to treat various conditions, including neuropathic pain, anxiety disorders, and epilepsy. It is available in various oral dosage forms, including capsules, tablets, and oral solutions. Healthcare facilities, specialty clinics, hospitals, homecare, hospital pharmacy, retail pharmacy, and online pharmacy are significant distribution channels for pregabalin.

The World Health Organization estimates that approximately 1.5 billion people worldwide live with chronic pain, creating a large potential patient population for pregabalin. Key disease conditions treated with pregabalin include neuropathic pain, anxiety disorders like generalized anxiety disorder and posttraumatic stress disorder, and epilepsy. Pregabalin works by modulating neurotransmitters and calcium channels In the central nervous system. It is also used to treat restless leg syndrome. Healthcare providers and patients increasingly prefer oral pregabalin due to its ease of administration and effectiveness. Clinical trials and generic manufacturers continue to expand the market by introducing new formulations and reducing costs.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise In the adoption of Pregabalin Industry?

Presence of large patient pool related to neuropathic pain is the key driver of the market.

• The market is driven by the large patient population suffering from neuropathic pain. Neuropathic pain is a type of chronic pain caused by damage or dysfunction of the peripheral or central nervous system. It is associated with various conditions such as diabetic neuropathy, chemotherapy-induced pain, shingles, and herniated disks. According to the World Health Organization, an estimated 7-10% of the global population experiences chronic pain, with neuropathic pain accounting for a significant portion. The geriatric population is particularly vulnerable, as the prevalence of neuropathic pain increases with age. In the US, for instance, the Centers for Disease Control and Prevention reported that in 2021, over 30 million people were diagnosed with diabetes, and 84.1
• million had prediabetes. Neuropathy affects approximately 50% of people with diabetes, making it a significant health concern. Pregabalin, an anticonvulsant medication, is effective in managing neuropathic pain, anxiety disorders such as generalized anxiety disorder and post-traumatic stress disorder, restless leg syndrome, and epilepsy. It is available in various oral dosage forms, including capsules, oral solutions, and tablets, catering to patient preference. Healthcare facilities, hospitals, specialty clinics, homecare, hospital pharmacy, retail pharmacy, and online pharmacy are key channels for the distribution of pregabalin. The drug is also used as anxiolytic medication and antiepileptic. The market growth is further fueled by the increasing number of clinical trials and the entry of generic manufacturers, expanding the availability and affordability of pregabalin to a larger patient population.

What are the market trends shaping the Pregabalin Industry?

Growing focus on emerging economies is the upcoming market trend.

• The global market for pregabalin is experiencing significant growth due to the increasing prevalence of conditions such as neuropathic pain, epilepsy, anxiety disorders, and fibromyalgia. These conditions are common in various regions, including China, India, and Brazil, where there is a growing focus on addressing the unmet needs In their treatment. The World Health Organization and other research institutes have issued guidelines to tailor treatments for each country, boosting the demand for pregabalin. As an anticonvulsant medication, pregabalin is effective in managing seizures and certain types of pain, including diabetic peripheral neuropathy and postherpetic neuralgia. It is available in various oral dosage forms, including capsules, tablets, and oral solutions, catering to patient preference.
• Healthcare facilities, hospitals, specialty clinics, homecare, hospital pharmacy, retail pharmacy, and online pharmacy are key distribution channels for pregabalin. As a treatment for anxiety disorders such as generalized anxiety disorder and posttraumatic stress disorder, pregabalin functions as an anxiolytic medication. The market growth is driven by the increasing patient population suffering from these disease conditions and the availability of generic manufacturers offering affordable alternatives.

What challenges does the Pregabalin Industry face during its growth?

Growing preference for alternatives is a key challenge affecting the industry growth.

• The market encompasses various applications in neuropathic pain, anxiety disorders, epilepsy, and fibromyalgia. According to the World Health Organization, chronic pain affects over 1.5 billion people globally, creating a significant demand for effective treatments. Pregabalin, an anticonvulsant medication, is used to manage neuropathic pain, anxiety disorders such as generalized anxiety disorder and posttraumatic stress disorder, epilepsy, and restless leg syndrome. Pregabalin functions by modulating neurotransmitters and calcium channels In the central nervous system. It is available in various oral dosage forms, including capsules, oral solution, and oral tablets. Healthcare facilities, hospitals, specialty clinics, homecare, hospital pharmacy, retail pharmacy, and online pharmacy are key distribution channels.
• However, the growing preference for alternative therapies may influence the market dynamics. Some alternative therapies, such as acids, L-carnitine, vitamins and minerals, herbal supplements, and traditional Chinese medicines, are gaining popularity for managing certain conditions like diabetic peripheral neuropathy, postherpetic neuralgia, and epilepsy. For instance, diabetic neuropathic pain can be alleviated by supplementing essential acids like alpha-lipoic acid, gamma-linolenic acid, and omega-3 fatty acids. L-carnitine, a substance produced and stored in various organs, including the liver and brain, has been reported to help diabetic patients regain sensation In their limbs when they increase its consumption In the form of acetyl-L-carnitine.
• Clinical trials and research are ongoing to evaluate the efficacy and safety of these alternative therapies, and generic manufacturers are introducing affordable options to cater to a diverse patient population with various disease conditions. Patient preference, accessibility, and affordability will significantly impact the market trends.

Exclusive Customer Landscape

The pregabalin market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the pregabalin market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, pregabalin market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

Biomax Biotechnics Pvt. Ltd. - The company provides a pharmaceutical solution In the form of extended-release Pregabalin 150mg tablets. These tablets are an essential component in managing certain neurological conditions, offering patients relief from symptoms associated with neuropathic pain and seizures.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Biomax Biotechnics Pvt. Ltd.
• Camber Pharmaceuticals Inc.
• Cipla Inc.
• Dr. Kumars Pharmaceuticals
• Genesis Biotec Inc.
• H. L. Healthcare Pvt. Ltd.
• Lupin Ltd.
• Medley Pharmaceuticals Ltd.
• MK Medicine
• MSN Laboratories
• Neuracle Lifesciences Pvt. Ltd.
• Novartis AG
• Pfizer Inc.
• Phoenix Biologicals Pvt. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Swastik Life Sciences
• Torrent Pharmaceuticals Ltd.
• Vibcare Pharma Pvt. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Pregabalin, an anticonvulsant medication, has gained significant attention In the healthcare industry due to its efficacy in managing various neurological conditions. This agent, which acts on calcium channels In the central nervous system, has been extensively studied for its role in alleviating neuropathic pain. Neuropathic pain, a type of chronic pain caused by damage or dysfunction of the peripheral nerves, affects a substantial patient population worldwide. Anxiety and sadness are common co-occurring conditions with neuropathic pain. Pregabalin has shown promising results in managing anxiety disorders such as generalized anxiety disorder and post-traumatic stress disorder. Furthermore, it has been used off-label for the treatment of restless leg syndrome and fibromyalgia, conditions that often accompany neuropathic pain.

The World Health Organization (WHO) recognizes the importance of addressing neuropathic pain, given its significant impact on quality of life and healthcare resources. Hospitals, specialty clinics, homecare, hospital pharmacy, retail pharmacy, and online pharmacy are some of the key healthcare facilities where patients can access pregabalin. Healthcare providers, including neurologists, psychiatrists, and primary care physicians, often prescribe this medication for their patients. Clinical trials have demonstrated pregabalin's efficacy in managing neuropathic pain associated with various disease conditions, such as epilepsy, diabetes-related peripheral neuropathy, and postherpetic neuralgia. Pregabalin is available in various oral dosage forms, including capsules, oral solutions, and oral tablets, catering to patient preferences and individual needs.

Antiepileptics, a class of anticonvulsant medications, share similar mechanisms of action with pregabalin. Neurotransmitters play a crucial role In the functioning of the central nervous system, and anticonvulsants, including pregabalin, modulate their activity to alleviate various neurological conditions. The geriatric population is particularly susceptible to neuropathic pain due to age-related changes In the nervous system. Pregabalin has shown to be effective in managing neuropathic pain in this population, making it an essential treatment option for healthcare providers. Lupin Pharmaceuticals, a global pharmaceutical company, is one of the significant players In the market for fibromyalgia agents. They offer pregabalin as an essential medication for managing fibromyalgia and related conditions.

Generic manufacturers also contribute to the market by providing affordable alternatives to branded versions of pregabalin. In conclusion, pregabalin's role in managing neuropathic pain, anxiety disorders, and other neurological conditions is well-established. Its availability in various oral dosage forms and accessibility through multiple channels, including hospitals, specialty clinics, homecare, retail pharmacies, and online pharmacies, make it a valuable treatment option for healthcare providers and their patients. The ongoing research and development efforts in this field aim to expand the therapeutic applications of pregabalin and improve patient outcomes.

Request Free Sample

What are the Key Data Covered in this Pregabalin Market Research and Growth Report?

• CAGR of the Pregabalin industry during the forecast period
• Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the pregabalin market growth of industry companies

We can help! Our analysts can customize this pregabalin market research report to meet your requirements.

Get in touch